Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for Treatment of gBRCA-mutated HER2-Negative Breast Cancer

U.S. Fast Track designation of ART6043 underpinned by promising clinical data to date and high unmet need in gBRCA-mutated HER2-negative breast ...
ascopubs.org

Pathway for the Development of ATR Inhibitors in Pediatric Malignancies: An ACCELERATE Multistakeholder Analysis

Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study High levels of DNA replication stress and defects in the ...

Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash

Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for ...
Yahoo Finance

Rakovina Therapeutics Reports Strong Industry Validation and Emerging Collaborations Following 9th Annual DDR Inhibitors Summit

Strategic Validation: Industry feedback confirms Rakovina’s approach targeting PTEN-deficient tumours with brain-penetrant ATR/mTOR inhibitors addresses critical gaps left by recent late-stage ...
Nasdaq

Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors

BRANFORD, Conn.--(BUSINESS WIRE)-- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced ...
BioWorld

Rakovina makes progress on ATR inhibitor program

Rakovina Therapeutics Inc. has reported progress in its AI-driven KT-5000AI program, advancing the development of precision ATR (ataxia telangiectasia and Rad3-related) inhibitors designed to disrupt ...
EurekAlert!

ATR inhibition using gartisertib in patient-derived glioblastoma cell lines

“[...] this study identifies gartisertib as a potent ATRi within patient-derived glioblastoma cell lines.” Glioblastoma cells can restrict the DNA-damaging ...
Cure Today

Phase 1/2 Trial Investigating ATR-04 for EGFRi-Related Rashes in Lung Cancer

ATR04-484 is a live biotherapeutic product targeting EGFR inhibitor-associated rashes in cancer patients, containing a modified Staphylococcus epidermidis strain. EGFR inhibitors, used in treating ...
Business Wire

Repare Therapeutics to Regain Global Rights to Camonsertib

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced today that it will ...